Pirtobrutinib significantly improved progression-free survival in untreated CLL/SLL patients compared to standard chemoimmunotherapy in the BRUIN CLL-313 trial. Early trends suggest potential overall ...
Pirtobrutinib combination therapy significantly improves progression free survival vs venetoclax and rituximab in relapsed or refractory CLL/SLL. Topline data were announced from a phase 3 trial ...
Add Yahoo as a preferred source to see more of our stories on Google. Lilly is further studying Jaypirca in multiple Phase III studies. Credit: AnnaStills / Shutterstock.com. (AnnaStills / ...
Johnson & Johnson’s (NYSE: LLY) Imbruvica is a covalent BTK inhibitor. Pirtobrutinib met its primary endpoint of non-inferiority on overall response rate (ORR) compared to ibrutinib (87.0% versus 78.5 ...
The newest BTK inhibitor on the market, Eli Lilly’s Jaypirca, has shown its chops in a head-to-head battle against the oldest treatment in the class, AbbVie and Johnson & Johnson’s Imbruvica. A phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results